Paper6392147
A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
Joss RA and 5 others. Invest New Drugs, 1984. Cited by 42 papers, by iCite.
Cite this record
ConductScience Library. A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule. Papers, record 6392147. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6392147
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A phase I trial of cis-diammine-1,1-cyclobutane dicarboxylate platinum II (Carboplatin, CBDCA, JM-8) with a single dose every five week-schedule.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Organoplatinum Compounds | Major topic |
| Adult | |
| Aged | |
| Blood | |
| Carboplatin | |
| Creatinine | |
| Digestive System | |
| Drug Administration Schedule | |
| Drug Evaluation | |
| Female | |
| Humans | |
| Kidney | |
| Male | |
| Middle Aged | |
| Neoplasms |
Source PubMed
References11
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 6342774 | New platinum complexes in clinical trials. | Cancer Treat Rev | 1983 | https://conductscience.org/library/papers/6342774 | PubMed |
| 2 | 227599 | Phase II trial of cis-dichlorodiammineplatinum(II) in advanced malignant lymphoma and small cell lung cancer: preliminary results. | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/227599 | PubMed |
| 3 | 387223 | Toxic effects of cis-dichlorodiammineplatinum(II) in man. | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/387223 | PubMed |
| 4 | 7198010 | Antitumor activity and toxicity of cisplatin analogs. | Cancer Treat Rep | 1982 | https://conductscience.org/library/papers/7198010 | PubMed |
| 5 | 6131277 | JMS, successor to cisplatin in advanced ovarian carcinoma? | Lancet | 1983 | https://conductscience.org/library/papers/6131277 | PubMed |
| 6 | 6761010 | Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6761010 | PubMed |
| 7 | 6258791 | High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium). | Cancer Treat Rep | 1980 | https://conductscience.org/library/papers/6258791 | PubMed |
| 8 | 6366128 | Phase I study of carboplatin given on a five-day intravenous schedule. | J Clin Oncol | 1983 | https://conductscience.org/library/papers/6366128 | PubMed |
| 9 | 378370 | Cisplatin (cis-diamminedichloroplatinum II). | Cancer Treat Rev | 1979 | https://conductscience.org/library/papers/378370 | PubMed |
| 10 | 498152 | Nephrotoxicity of cis-dichlorodiammineplatinum(II). | Cancer Treat Rep | 1979 | https://conductscience.org/library/papers/498152 | PubMed |
| 11 | 6347373 | A phase I and pharmacokinetic study of diamminecyclobutane-dicarboxylatoplatinum (NSC 241240). | Cancer Res | 1983 | https://conductscience.org/library/papers/6347373 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 28060758 | Exosomes as mediators of platinum resistance in ovarian cancer. | Oncotarget | 2017 | https://conductscience.org/library/papers/28060758 | PubMed |
| 8880388 | New drug development for pediatric oncology. | Invest New Drugs | 1996 | https://conductscience.org/library/papers/8880388 | PubMed |
| 3689665 | Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial. | Br J Cancer | 1987 | https://conductscience.org/library/papers/3689665 | PubMed |
| 2559261 | Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: a dose escalation study of carboplatin. UCL Clinical Oncology Group. | Med Oncol Tumor Pharmacother | 1989 | https://conductscience.org/library/papers/2559261 | PubMed |
| 2191847 | Antineoplastic drugs in 1990. A review (Part II). | Drugs | 1990 | https://conductscience.org/library/papers/2191847 | PubMed |
| 2178792 | A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP. | Cancer Chemother Pharmacol | 1990 | https://conductscience.org/library/papers/2178792 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6392147
GET https://conductscience.org/api/papers/v1/6392147/authors